Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAVE Long-term Safety and Efficacy Study of Durvalumab
2019-001402-20Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of durvalumab in Nonhematologic neoplasms and cancer, sponsored by AstraZeneca. Primary endpoint: All serious adverse events. Started Oct 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2019-001402-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001402-20.